CLAIMS

I claim:

1. A method for inhibiting the proliferation of tumor cells, comprising administering to the tumor cells a composition that comprises an antibody component, wherein the antibody component binds both the B-cell maturation antigen (BCMA) and the transmembrane activator and calcium-modulator and cyclophilin ligand-interactor (TACI).

2. The method of claim 1, wherein the composition is administered to cells cultured *in vitro*.

3. The method of claim 1, wherein the composition is a pharmaceutical composition, and wherein the pharmaceutical composition is administered to a subject, which has a tumor.

4. The method of claim 1, wherein the composition comprises an anti-BCMA-TACI antibody component that is a naked BCMA-TACI antibody.

5. The method of claim 1, wherein the composition comprises an anti-BCMA-TACI antibody component that is a naked BCMA-TACI antibody fragment.

6. The method of claim 1, wherein the composition comprises an immunoconjugate that comprises an anti-BCMA-TACI antibody component and a therapeutic agent.

7. The method of claim 6, wherein the therapeutic agent is selected from the group consisting of chemotherapeutic drug, cytotoxin, immunomodulator, chelator, boron compound, photoactive agent, photoactive dye, and radioisotope.

8. The method of claim 1, wherein the composition comprises an antibody fusion protein that comprises an anti-BCMA-TACI antibody component and a cytotoxic polypeptide.

9. The method of claim 1, further comprising administering a composition that comprises an antibody component, which binds to an epitope within a polypeptide consisting of amino acid residues 105 to 166 of SEQ ID NO:4.

10. The method of claim 9, wherein the antibody component binds to a polypeptide consisting of amino acid residues 110 to 118 of SEQ ID NO:4.

11. A method for inhibiting ZTNF4 activity in a mammal, comprising administering a composition that comprises an anti-BCMA-TACI antibody component to the mammal.

12. The method of claim 11, wherein the ZTNF4 activity is associated with increased endogenous antibody production.

13. The method of claim 11, wherein the ZTNF4 activity is associated with a disorder selected from the group consisting of neoplasm, chronic lymphocytic leukemia, multiple myeloma, non-Hodgkin's lymphoma, post-transplantation lymphoproliferative disease, and light chain gammopathy.

14. The method of claim 11, wherein the ZTNF4 activity is associated with inflammation, and wherein administration of the composition decreases inflammation.

15. A method for inhibiting the proliferation of tumor cells, comprising administering to the tumor cells a multispecific antibody composition, wherein the multispecific antibody composition comprises:

(a) an antibody component that binds the extracellular domain of the B-cell maturation antigen (BCMA), and

(b) an antibody component that binds the extracellular domain of transmembrane activator and calcium-modulator and cyclophilin ligand-interactor (TACI), wherein the anti-TACI antibody component does not bind the extracellular domain of BCMA,

wherein the administration of the multispecific antibody composition inhibits the proliferation of tumor cells.

16. The method of claim 15, wherein the multispecific antibody composition is administered to cells cultured *in vitro*.

17. The method of claim 15, wherein the multispecific antibody composition is a pharmaceutical composition, and wherein the pharmaceutical composition is administered to a subject, which has a tumor.

18. The method of claim 15, wherein the multispecific antibody composition comprises an anti-BCMA naked antibody component and an anti-TACI naked antibody component.

19. The method of claim 15, wherein the multispecific antibody composition comprises bispecific antibodies that bind BCMA and TACI.

20. The method of claim 15, wherein at least one of the antibody components further comprises a therapeutic agent.

21. The method of claim 20, wherein the therapeutic agent is selected from the group consisting of chemotherapeutic drug, cytotoxin, immunomodulator, chelator, boron compound, photoactive agent, photoactive dye, and radioisotope.

22. The method of claim 16, wherein the multispecific antibody composition comprises: (a) an antibody fusion protein that comprises a cytotoxic polypeptide, and (b) at least one of an anti-BCMA antibody component or an anti-TACI antibody component.

23. The method of claim 15, wherein the tumor cells are lymphoma cells.

24. An antibody component that specifically binds with both the B-cell maturation antigen (BCMA) and transmembrane activator and calcium-modulator and cyclophilin ligand-interactor (TACI).